Overview and Scope
The non-alcoholic steatohepatitis treatment refers to a treatment used in steatohepatitis by maintaining a healthy diet, control of blood sugar, loss of body weight and fat. It is a treatment type for liver disease in which people who drink little, or no alcohol develop fatty livers. This causes liver cell destruction and inflammation, which can lead to cirrhosis.
Sizing and Forecast
The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $1.89 billion in 2024 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%. The growth in the historic period can be attributed to rising prevalence of nash, growing awareness and diagnosis, lifestyle changes and obesity epidemic, clinical research, healthcare infrastructure and access, regulatory support and clinical trials..
The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%. The growth in the forecast period can be attributed to advancements in drug development, increased disease awareness, rising prevalence and risk factor, shift towards personalized medicine.. Major trends in the forecast period include patient-centric approach, technological advancements, targeted therapies, regulatory landscape, advancements in research..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report
Segmentation & Regional Insights
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Top 5 Major Players:
- AstraZeneca PLC,
- Tobira Therapeutics Inc.,
- Galmed Pharmaceuticals Ltd.,
- Genfit S.A.,
- Zydus Cadila Healthcare Limited
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
Major Driver Impacting Market Growth
An increased prevalence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market going forward. Insulin resistance occurs when muscles, fat, and liver cells do not respond adequately to insulin and cannot easily absorb glucose from the blood, causing high blood sugar. These are linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The use of insulin resistance has multiplied due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, according to a report from International Diabetes Federation, a Belgium-based global diabetes community, diabetes affects 537 million individuals (20-79 years old), accounting for one in every ten, which is expected to increase to 643 million by 2030 and 783 million by 2045. Furthermore, in March 2024, according to a report published by the Office for Health Improvement and Disparities, a UK government department, the number of premature deaths from liver disease witnessed a 3.7% increase, totaling 10,501 in 2021. Among these fatalities, 5,686 were attributed to alcohol-related liver disease in England, while non-alcoholic fatty liver disease accounted for 320 premature deaths. Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment market.
Key Industry Players
Major companies operating in the non-alcoholic steatohepatitis treatment market report are AstraZeneca Plc, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corp., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Gemphire Therapeutics Inc., Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Sinew Pharma Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG, Asahi Kasei Corporation
The non-alcoholic steatohepatitis treatment market report table of contents includes:
1. Executive Summary
2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics
3. Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies
4. Non-Alcoholic Steatohepatitis Treatment Market – Macro Economic Scenario
5. Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth
…..
31. Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Benchmarking
32. Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market
34. Non-Alcoholic Steatohepatitis Treatment Market Future Outlook and Potential Analysis
35. Appendix
List of Tables:
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
…..
Table 74: AstraZeneca Plc Financial Performance
Table 75: Tobira Therapeutics Inc. Financial Performance
Table 76: Galmed Pharmaceuticals Ltd. Financial Performance
Table 77: Genfit S.A. Financial Performance
Table 78: Zydus Cadila Healthcare Limited Financial Performance
Explore the trending research reports from TBRC:
https://topprnews.com/anti-money-laundering-software-market-share/
https://topprnews.com/automated-dispensing-machines-market-size/
https://topprnews.com/b2c-mobility-sharing-market-analysis/
https://goodprnews.com/anti-money-laundering-software-market-size/
https://goodprnews.com/automated-dispensing-machines-market-share/
https://goodprnews.com/b2c-mobility-sharing-market-analysis/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
